One of the difficulties in the use of reprogrammed cells (iPS cells) is the low efficiency. Now, a technical step has been taken to substantially increase this. Using it, Australian researchers, combining it with the genome editing technique CRISPR-Cas9, have been able to generate normal cells from the cells of two patients, one with retinal cell degeneration and the other a child with severe immune deficiency, which opens the door to its possible clinical use.


Subscribe to our newsletter:

We don’t spam! Read our privacy policy for more info.